<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>30(10)</volume><submitter>Lin AY</submitter><pubmed_abstract>Inclusion body myositis is the most commonly acquired myopathy after the age of 45. The slowly progressive and heterogeneous disorder is a challenge for measuring clinical trial efficacy. One current method for measuring progression utilizes the Inclusion Body Myositis-Functional Rating Scale. We have found that the upper extremity domain scores in the Inclusion Body Myositis-Functional Rating Scale do not consistently change until there is extreme loss of grip and finger flexor strength. Therefore, we performed a cross-sectional observational study of 83 inclusion body myositis patients and 38 controls recruited at the 2019 Annual Patient Conference of The Myositis Association. We evaluated new Inclusion Body Myositis Patient-Reported Outcome measures for upper extremity function modified from the NIH Patient-Reported Outcomes Measurement Information System as well as pinch and grip strength. We found that Patient-Reported Outcome measures hand-function have a higher correlation with pinch and grip strength than the Inclusion Body Myositis-Functional Rating Scale.</pubmed_abstract><journal>Neuromuscular disorders : NMD</journal><pagination>807-814</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9756909</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Optimizing hand-function patient outcome measures for inclusion body myositis.</pubmed_title><pmcid>PMC9756909</pmcid><pubmed_authors>Weihl CC</pubmed_authors><pubmed_authors>Seiffert M</pubmed_authors><pubmed_authors>Wang LH</pubmed_authors><pubmed_authors>Faino AV</pubmed_authors><pubmed_authors>Lin AY</pubmed_authors><pubmed_authors>Siener CS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Optimizing hand-function patient outcome measures for inclusion body myositis.</name><description>Inclusion body myositis is the most commonly acquired myopathy after the age of 45. The slowly progressive and heterogeneous disorder is a challenge for measuring clinical trial efficacy. One current method for measuring progression utilizes the Inclusion Body Myositis-Functional Rating Scale. We have found that the upper extremity domain scores in the Inclusion Body Myositis-Functional Rating Scale do not consistently change until there is extreme loss of grip and finger flexor strength. Therefore, we performed a cross-sectional observational study of 83 inclusion body myositis patients and 38 controls recruited at the 2019 Annual Patient Conference of The Myositis Association. We evaluated new Inclusion Body Myositis Patient-Reported Outcome measures for upper extremity function modified from the NIH Patient-Reported Outcomes Measurement Information System as well as pinch and grip strength. We found that Patient-Reported Outcome measures hand-function have a higher correlation with pinch and grip strength than the Inclusion Body Myositis-Functional Rating Scale.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Oct</publication><modification>2025-05-29T16:30:11.867Z</modification><creation>2025-05-29T16:30:11.867Z</creation></dates><accession>S-EPMC9756909</accession><cross_references><pubmed>32928647</pubmed><doi>10.1016/j.nmd.2020.08.358</doi></cross_references></HashMap>